John Libbey Eurotext


Les anti-angiogéniques bientôt en traitement adjuvant ? Volume 12, numéro 1, Mars 2017

  • [1] Paez-Ribes M, Allen E, Hudock J. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31.
  • [2] de Gramont A, Van Cutsem, Schmoll HJ. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225-33.
  • [3] Allegra CJ, Yothers G, O MJ. Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial. J Clin Oncol. 2013;31:359-64.
  • [4] Haas NB, Manola J, Uzzo RG. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008-16.
  • [5] Bell R, Brown J, Parmar M. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2016;Dec 19 [Epub ahead of print].
  • [6] Kerbel RS. A cancer therapy resistant to resistance. Nature. 1997;390:335-6.